Condition: Myelodysplastic Syndrome With Excess Blasts · Recurrent Acute Myeloid Leukemia · Recurrent Myelodysplastic Syndrome · Sponsor: National Cancer Institute (NCI)
This phase I trial studies the side effects and best dose of TAK-243 in treating patients with acute myeloid leukemia or myelodysplastic syndromes with increased blasts that has come back (relapsed) or that is not responding to treatment (refractory). TAK-243 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Recruiting |
| VCU Massey Comprehensive Cancer Center | Richmond, Virginia, United States | Recruiting |
| University Health Network-Princess Margaret Hospital | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03816319